Is the response to growth hormone in short children born small for gestational age dependent on genetic or maternal factors?

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The researchers investigated whether genetic or maternal/environmental risk factors for being born small for gestational age (SGA), e.g.

Silver-Russell syndrome, congenital heart defects, infections of mothers or smoking during pregnancy, explain the variation in the first-year growth response to GH therapy.

Who Took Part

The abstract describes 135 children taking part.

By PubMed's age tags, the people studied were young children and children, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Body Height, Child Development, Heart Defects, Congenital, Human Growth Hormone, Infant, Small for Gestational Age, Infections and Risk Factors.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 135 children.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Hormone research), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.